{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:19:36Z","timestamp":1793330376288,"version":"4.5.0"},"reference-count":173,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["81972931 to HF, 2020KY558 to JQ, LY20H110001 to YL"],"award-info":[{"award-number":["81972931 to HF, 2020KY558 to JQ, LY20H110001 to YL"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.594735","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T03:32:57Z","timestamp":1605583977000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":375,"title":["The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside"],"prefix":"10.3389","volume":"11","author":[{"given":"Taoming","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuni","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunli","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201701242RR","article-title":"IL-17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo","volume":"32","author":"Zhou","year":"2018","journal-title":"FASEB J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601540","article-title":"IL-17A-Induced PLET1 Expression Contributes to Tissue Repair and Colon Tumorigenesis","volume":"199","author":"Zepp","year":"2017","journal-title":"J\u00a0Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.02.042","article-title":"IL-17-Mediated Immunity Controls Skin\u00a0Infection and T Helper 1 Response during Experimental Microsporum canis\u00a0Dermatophytosis","volume":"138","author":"Burstein","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01611","article-title":"IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis","volume":"9","author":"Park","year":"2018","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/atvbaha.114.304108","article-title":"Interleukin 17 drives vascular inflammation, endothelial dysfunction, and arterial hypertension in psoriasis-like skin disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.jid.2019.01.021","article-title":"IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation","volume":"139","author":"Senra","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"330ra37","DOI":"10.1126\/scitranslmed.aad8996","article-title":"Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts","volume":"8","author":"Ulu\u00e7kan","year":"2016","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.01.006","article-title":"Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes","volume":"139","author":"Moos","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aau9657","article-title":"Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation","volume":"4","author":"Su","year":"2019","journal-title":"Sci Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.383","article-title":"Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6","volume":"135","author":"Wu","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02107","article-title":"Characteristic Pattern of IL-17RA, IL-17RB, and IL-17RC in Monocytes\/Macrophages and Mast Cells From Patients With Bullous Pemphigoid","volume":"10","author":"Nesmond","year":"2019","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.21342","article-title":"Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis","volume":"52","author":"Koenders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.013","article-title":"The Costimulatory Receptor OX40 Inhibits Interleukin-17 Expression through Activation of Repressive Chromatin Remodeling Pathways","volume":"44","author":"Xiao","year":"2016","journal-title":"Immunity"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41467-018-07911-6","article-title":"RORgammat inhibition selectively targets IL-17 producing iNKT and gammadelta-T cells enriched in Spondyloarthritis patients","volume":"10","author":"Venken","year":"2019","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13048","article-title":"Tiam1\/Rac1 complex controls Il17a transcription and autoimmunity","volume":"7","author":"Kurdi","year":"2016","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41467-019-08605-3","article-title":"Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation","volume":"10","author":"Cho","year":"2019","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2020.02.004","article-title":"Structural Analysis Reveals that the Cytokine IL-17F Forms a Homodimeric Complex with Receptor IL-17RC to Drive IL-17RA-Independent Signaling","volume":"52","author":"Goepfert","year":"2020","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903739","article-title":"IL-17RC is required for immune signaling via an extended SEF\/IL-17R signaling domain in the cytoplasmic tail","volume":"185","author":"Ho","year":"2010","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.121418","article-title":"SEF\/IL-17R (SEFIR) is not enough: an extended SEFIR domain is required for il-17RA-mediated signal transduction","volume":"285","author":"Onishi","year":"2010","journal-title":"J Biol Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1107\/S1399004714005227","article-title":"Structure of the unique SEFIR domain from human interleukin 17 receptor A reveals a composite ligand-binding site containing a conserved alpha-helix for Act1 binding and IL-17 signaling","volume":"70","author":"Zhang","year":"2014","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ni1439","article-title":"The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease","volume":"8","author":"Qian","year":"2007","journal-title":"Nat Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M703250200","article-title":"Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1\/2-dependent NF-kappaB and C\/EBPbeta activation","volume":"282","author":"Patel","year":"2007","journal-title":"J Biol Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C600256200","article-title":"Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor","volume":"281","author":"Chang","year":"2006","journal-title":"J Biol Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2080","article-title":"The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation","volume":"12","author":"Bulek","year":"2011","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150204","article-title":"A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis","volume":"212","author":"Wu","year":"2015","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2081","article-title":"Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)","volume":"12","author":"Sun","year":"2011","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100703","article-title":"Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling","volume":"207","author":"Zhu","year":"2010","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"ra44","DOI":"10.1126\/scisignal.2003699","article-title":"The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling","volume":"6","author":"Garg","year":"2013","journal-title":"Sci Signal"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14034","article-title":"Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris","volume":"174","author":"Chiricozzi","year":"2016","journal-title":"Br J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03704.x","article-title":"Serum cytokines and growth factor levels in Japanese patients with psoriasis","volume":"35","author":"Takahashi","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br J Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15533","article-title":"Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin","volume":"177","author":"Dyring-Andersen","year":"2017","journal-title":"Br J Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.033","article-title":"Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis","volume":"136","author":"Mashiko","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15358","article-title":"IL-17A localizes in the exocytic compartment of mast cells in psoriatic skin","volume":"177","author":"Brembilla","year":"2017","journal-title":"Br J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014108","article-title":"Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis","volume":"5","author":"Res","year":"2010","journal-title":"PLoS One"},{"key":"B46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdermsci.2016.10.007","article-title":"Potential role of IL-17-producing CD4\/CD8 double negative alphabeta T cells in psoriatic skin inflammation in a TPA-induced STAT3C transgenic mouse model","volume":"85","author":"Ueyama","year":"2017","journal-title":"J Dermatol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41590-019-0423-0","article-title":"c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies","volume":"20","author":"Bernink","year":"2019","journal-title":"Nat Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.146","article-title":"Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients","volume":"134","author":"Teunissen","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1038\/ncomms8001","article-title":"Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci","volume":"6","author":"Tsoi","year":"2015","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte antigen triggers autoimmunity in human psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J Exp Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.immuni.2018.05.012","article-title":"Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A","volume":"49","author":"Wang","year":"2018","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J Exp Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41467-018-07911-6","article-title":"ROR\u03b3t inhibition selectively targets IL-17 producing iNKT and \u03b3\u03b4-T cells enriched in Spondyloarthritis patients","volume":"10","author":"Venken","year":"2019","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.07.006","article-title":"Anti-IL-17A and IL-23p19 antibodies but not anti-TNF\u03b1 antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis","volume":"95","author":"Shimizu","year":"2019","journal-title":"J Dermatol Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x19886505","article-title":"The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis","volume":"11","author":"Frischknecht","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.immuni.2015.06.024","article-title":"Growth Factor FGF2 Cooperates with Interleukin-17 to Repair Intestinal Epithelial Damage","volume":"43","author":"Song","year":"2015","journal-title":"Immunity"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10928","article-title":"IL-17-producing \u03b3\u03b4 T cells enhance bone regeneration","volume":"7","author":"Ono","year":"2016","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.immuni.2020.06.004","article-title":"Excessive Polyamine Generation in Keratinocytes Promotes Self-RNA Sensing by Dendritic Cells in Psoriasis","volume":"53","author":"Lou","year":"2020","journal-title":"Immunity"},{"key":"B63","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy","volume":"16","author":"van Baarsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204782","article-title":"IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis","volume":"74","author":"Adamopoulos","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: A prospective population-based cohort study","volume":"78","author":"Wan","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.immuni.2018.03.019","article-title":"An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation","volume":"48","author":"Xu","year":"2018","journal-title":"Immunity"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.036","article-title":"Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis","volume":"138","author":"Vandeghinste","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.06.009","article-title":"Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis","volume":"136","author":"Senra","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700499200","article-title":"Identification of an interleukin 17F\/17A heterodimer in activated human CD4+ T cells","volume":"282","author":"Wright","year":"2007","journal-title":"J Biol Chem"},{"key":"B75","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.19262","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study","volume-title":"Br J Dermatol","author":"Reich","year":"2020"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5\u00a0years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","article-title":"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study","volume":"20","author":"Kampylafka","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5","volume":"59","author":"van der Heijde","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.032","article-title":"Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study","volume":"79","author":"Leonardi","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis","volume":"145","author":"Tomalin","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)","volume-title":"Br J Dermatol","author":"Papp","year":"2020"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.007","article-title":"Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed","volume":"81","author":"Kimmel","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17318","article-title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials","volume":"180","author":"Langley","year":"2019","journal-title":"Br J Dermatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702","article-title":"Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br J Dermatol"},{"key":"B94","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study","volume-title":"J Am Acad Dermatol","author":"Blauvelt","year":"2020"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"B97","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume-title":"Rheumatol (Oxford)","author":"Genovese","year":"2020"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.095","article-title":"Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial","volume":"82","author":"Puig","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2016.09.026","article-title":"Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data","volume":"76","author":"Strober","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16254","article-title":"Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review","volume":"34","author":"Fowler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1727439","article-title":"Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature","volume":"20","author":"Caldarola","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17779","article-title":"Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition","volume":"181","author":"Napolitano","year":"2019","journal-title":"Br J Dermatol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review","volume":"34","author":"Al-Janabi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J Exp Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.10.001","article-title":"IL-17 Receptor Signaling in Oral Epithelial Cells Is Critical for Protection against Oropharyngeal Candidiasis","volume":"20","author":"Conti","year":"2016","journal-title":"Cell Host Microbe"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3211","article-title":"T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26","volume":"16","author":"Meller","year":"2015","journal-title":"Nat Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax7965","article-title":"Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A\/F and TGF-\u03b2","volume":"4","author":"Li","year":"2019","journal-title":"Sci Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19018","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u2265 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study","volume":"183","author":"Philipp","year":"2020","journal-title":"Br J Dermatol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"B114","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.011","article-title":"Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using (18)F-fluorodeoxyglucose PET\/CT","volume":"80","author":"Kim","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18484","article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies","volume":"182","author":"Kimball","year":"2020","journal-title":"Br J Dermatol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0141","article-title":"Association of Hidradenitis Suppurativa With T Helper 1\/T Helper 17 Phenotypes: A Semantic Map Analysis","volume":"154","author":"Thomi","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12234","article-title":"Myeloid marker S100A8\/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity","volume":"168","author":"Wieland","year":"2013","journal-title":"Br J Dermatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1365-2133.2011.10643.x","article-title":"Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions","volume":"166","author":"van der Zee","year":"2012","journal-title":"Br J Dermatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid","volume":"134","author":"Le Jan","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17822","article-title":"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa","volume":"181","author":"Prussick","year":"2019","journal-title":"Br J Dermatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study","volume":"83","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jaci.2009.03.041","article-title":"IL-22-producing \u201cT22\u201d T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells","volume":"123","author":"Nograles","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.jaci.2009.09.031","article-title":"Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis","volume":"124","author":"Guttman-Yassky","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.09.031","article-title":"Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood","volume":"145","author":"Czarnowicki","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis","volume":"132","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1111\/all.12633","article-title":"Mutual upregulation of endothelin-1 and IL-25 in atopic dermatitis","volume":"70","author":"Aktar","year":"2015","journal-title":"Allergy"},{"key":"B142","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jaci.2009.05.042","article-title":"Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen","volume":"124","author":"Oyoshi","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01412.x","article-title":"IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion","volume":"21","author":"Gutowska-Owsiak","year":"2012","journal-title":"Exp Dermatol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.277","article-title":"IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction","volume":"131","author":"Hvid","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130351","article-title":"A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis","volume":"210","author":"Salimi","year":"2013","journal-title":"J Exp Med"},{"key":"B146","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.04.055","article-title":"Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis","volume-title":"J Allergy Clin Immunol","author":"Ungar","year":"2020"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1406894","article-title":"A systematic review of ustekinumab in the treatment of atopic dermatitis","volume":"29","author":"Pan","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"B148","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15493","article-title":"Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study","volume":"177","author":"Saeki","year":"2017","journal-title":"Br J Dermatol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13325","article-title":"Dissecting susceptibility from exogenous triggers: the model of alopecia areata and associated inflammatory skin diseases","volume":"29","author":"Garzorz","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12808","article-title":"Bayoumy NM. T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-\u03b1) in patients with alopecia areata: association with clinical type and severity","volume":"55","author":"Atwa","year":"2016","journal-title":"Int J Dermatol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12396","article-title":"T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata","volume":"169","author":"Tembhre","year":"2013","journal-title":"Br J Dermatol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12978","article-title":"Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata","volume":"42","author":"Han","year":"2015","journal-title":"J Dermatol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14775","article-title":"Role of T helper 17 cells and T regulatory cells in alopecia areata: comparison of lesion and serum cytokine between controls and patients","volume":"32","author":"Loh","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.014","article-title":"IL-12\/IL-23 neutralization is ineffective for alopecia areata in mice and humans","volume":"144","author":"Ortolan","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1853-5","article-title":"Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata","volume":"310","author":"Guttman-Yassky","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.5384","article-title":"Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris","volume":"153","author":"Feldmeyer","year":"2017","journal-title":"JAMA Dermatol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaad.2018.03.036","article-title":"Biologics for pityriasis rubra pilaris treatment: A review of the literature","volume":"79","author":"Napolitano","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.3885","article-title":"Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab","volume":"152","author":"Schuster","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0932","article-title":"Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial","volume":"156","author":"Haynes","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14114","article-title":"Ustekinumab treatment of pityriasis rubra pilaris: A report of five cases","volume":"45","author":"Napolitano","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/463928","article-title":"Overexpression of interleukin-23 and interleukin-17 in the lesion of pemphigus vulgaris: a preliminary study","volume":"2014","author":"Xue","year":"2014","journal-title":"Mediators Inflamm"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7151285","article-title":"Th1\/Th17-Related Cytokines and Chemokines and Their Implications in the Pathogenesis of Pemphigus Vulgaris","volume":"2017","author":"Timoteo","year":"2017","journal-title":"Mediators Inflamm"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8206983","article-title":"Involvement of the IL23\/Th17 Pathway in the Pathogenesis of Tunisian Pemphigus Foliaceus","volume":"2018","author":"Ben Jmaa","year":"2018","journal-title":"Mediators Inflamm"},{"key":"B165","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14071","article-title":"Decreased serum levels of interleukin-17, interleukin-23, TGF-\u03b2 in pemphigus vulgaris patients, and their association with disease phase","volume-title":"Dermatol Ther","author":"Gholibeigian","year":"2020"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.11.015","article-title":"A role for Th1-like Th17 cells in the pathogenesis of inflammatory and autoimmune disorders","volume":"105","author":"Kamali","year":"2019","journal-title":"Mol Immunol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26772","article-title":"The imbalance of circulating T helper subsets and regulatory T cells in patients with LRBA deficiency: Correlation with disease severity","volume":"233","author":"Azizi","year":"2018","journal-title":"J Cell Physiol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.09.037","article-title":"Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis","volume":"108","author":"Mo","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2014.12.008","article-title":"The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis","volume":"76","author":"Zhou","year":"2015","journal-title":"Hum Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13982","article-title":"CCL3, IL-7, IL-13 and IFN\u03b3 transcripts are increased in skin\u2019s biopsy of systemic sclerosis","volume":"28","author":"Gon\u00e7alves","year":"2019","journal-title":"Exp Dermatol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2019.84738","article-title":"Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis","volume":"15","author":"Robak","year":"2019","journal-title":"Arch Med Sci"},{"key":"B172","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1186\/ar4430","article-title":"Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction","volume":"16","author":"Yang","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B173","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1186\/s13075-014-0512-2","article-title":"Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway","volume":"16","author":"Liu","year":"2014","journal-title":"Arthritis Res Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.594735\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T09:51:01Z","timestamp":1697104261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.594735\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":173,"alternative-id":["10.3389\/fimmu.2020.594735"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.594735","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,17]]},"article-number":"594735"}}